High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: Results of the MOSCATO 01 trial

Christophe Massard, Stefan Michiels, Charles Ferté, Marie Cécile Le Deley, Ludovic Lacroix, Antoine Hollebecque, Loic Verlingue, Ecaterina Ileana, Silvia Rosellini, Samy Ammari, Maud Ngo-Camus, Rastislav Bahleda, Anas Gazzah, Andrea Varga, Sophie Postel-Vinay, Yohann Loriot, Caroline Even, Ingrid Breuskin, Nathalie Auger, Bastien JobThierry De Baere, Frederic Deschamps, Philippe Vielh, Jean Yves Scoazec, Vladimir Lazar, Catherine Richon, Vincent Ribrag, Eric Deutsch, Eric Angevin, Gilles Vassal, Alexander Eggermont, Fabrice André, Jean Charles Soria

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

523 Citaten (Scopus)

Samenvatting

High-throughput genomic analyses may improve outcomes in patients with advanced cancers. MOSCATO 01 is a prospective clinical trial evaluating the clinical benefit of this approach. Nucleic acids were extracted from fresh-frozen tumor biopsies and analyzed by array comparative genomic hybridization, next-generation sequencing, and RNA sequencing. The primary objective was to evaluate clinical benefit as measured by the percentage of patients presenting progression- free survival (PFS) on matched therapy (PFS2) 1.3-fold longer than the PFS on prior therapy (PFS1). A total of 1,035 adult patients were included, and a biopsy was performed in 948. An actionable molecular alteration was identified in 411 of 843 patients with a molecular portrait. A total of 199 patients were treated with a targeted therapy matched to a genomic alteration. The PFS2/PFS1 ratio was >1.3 in 33% of the patients (63/193). Objective responses were observed in 22 of 194 patients (11%; 95% CI, 7%-17%), and median overall survival was 11.9 months (95% CI, 9.5-14.3 months). SIGNIFICANCE: This study suggests that high-throughput genomics could improve outcomes in a subset of patients with hard-to-treat cancers. Although these results are encouraging, only 7% of the successfully screened patients benefited from this approach. Randomized trials are needed to validate this hypothesis and to quantify the magnitude of benefit. Expanding drug access could increase the percentage of patients who benefit.

Originele taal-2Engels
Pagina's (van-tot)586-595
Aantal pagina's10
TijdschriftCancer Discovery
Volume7
Nummer van het tijdschrift6
DOI's
StatusGepubliceerd - 2017
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: Results of the MOSCATO 01 trial'. Samen vormen ze een unieke vingerafdruk.

Citeer dit